Moleculin Biotech Inc. (MBRX) Financial Statements (2024 and earlier)

Company Profile

Business Address 5300 MEMORIAL DRIVE
HOUSTON, TX 77007
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments23,550,00043,145,00070,903,00015,173,00010,735,0007,134,000
Cash and cash equivalents23,550,00043,145,00070,903,00015,173,00010,735,0007,134,000
Receivables 95,00022,00045,0001,00010,000 
Prepaid expense 564,000600,000589,000743,0002,749,000840,000
Other undisclosed current assets2,064,0001,829,000960,0001,281,000(10,000) 
Total current assets:26,273,00045,596,00072,497,00017,198,00013,484,0007,974,000
Noncurrent Assets
Operating lease, right-of-use asset524,000403,000107,000202,000287,000
Property, plant and equipment272,000275,000338,000483,000316,000463,000
Intangible assets, net (including goodwill), including:11,148,00011,148,00011,148,00011,148,00011,148,00011,148,000
Intangible assets, net (excluding goodwill) 11,100,00011,100,00011,100,00011,100,000  
Other undisclosed intangible assets, net (including goodwill)48,00048,00048,00048,00011,148,00011,148,000
Total noncurrent assets:11,944,00011,826,00011,593,00011,833,00011,751,00011,611,000
TOTAL ASSETS:38,217,00057,422,00084,090,00029,031,00025,235,00019,585,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,815,0004,819,0003,622,0002,920,0003,570,0003,548,000
Accounts payable2,498,0002,095,0001,364,0001,129,0002,153,0001,246,000
Accrued liabilities4,317,0002,724,0002,258,0001,791,0001,417,0002,302,000
Deferred compensation liability      150,000
Derivative instruments and hedges, liabilities      180,000
Total current liabilities:6,815,0004,819,0003,622,0002,920,0003,570,0003,878,000
Noncurrent Liabilities
Long-term debt and lease obligation:   63,000159,000276,000 
Liabilities, other than long-term debt5,329,000412,0001,412,0008,192,0005,818,0001,435,000
Deferred rent credit      107,000
Operating lease, liability474,000335,00063,000159,000276,000
Derivative instruments and hedges, liabilities4,855,00077,0001,412,0008,192,0005,818,0001,328,000
Total noncurrent liabilities:5,329,000412,0001,475,0008,351,0006,094,0001,435,000
Total liabilities:12,144,0005,231,0005,097,00011,271,0009,664,0005,313,000
Equity
Equity, attributable to parent, including:26,073,00052,191,00078,993,00017,760,00015,571,00014,272,000
Common stock33,00029,00029,00069,00046,00029,000
Common stock, share subscribed but unissued, subscriptions receivable    (129,000)  
Additional paid in capital157,653,000153,985,000151,733,00074,671,00055,055,00040,564,000
Accumulated deficit(131,604,000)(101,835,000)(72,810,000)(56,916,000)(39,561,000)(26,356,000)
Other undisclosed equity, attributable to parent(9,000)12,00041,00065,00031,00035,000
Total equity:26,073,00052,191,00078,993,00017,760,00015,571,00014,272,000
TOTAL LIABILITIES AND EQUITY:38,217,00057,422,00084,090,00029,031,00025,235,00019,585,000

Income Statement (P&L) (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues      
Sublease income     
Gross profit:      
Operating expenses(29,631,000)(30,640,000)(22,968,000)(19,742,000)(17,524,000)(15,025,000)
Other undisclosed operating loss      
Operating loss:(29,631,000)(30,640,000)(22,968,000)(19,742,000)(17,524,000)(15,025,000)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
48,00040,00040,00028,00015,000(40,000)
Loss from continuing operations before equity method investments, income taxes:(29,583,000)(30,600,000)(22,928,000)(19,714,000)(17,509,000)(15,065,000)
Other undisclosed income from continuing operations before income taxes    2,359,000  
Loss from continuing operations before income taxes:(29,583,000)(30,600,000)(22,928,000)(17,355,000)(17,509,000)(15,065,000)
Income tax benefit     229,000 
Loss from continuing operations:(29,583,000)(30,600,000)(22,928,000)(17,355,000)(17,280,000)(15,065,000)
Loss before gain (loss) on sale of properties:(22,928,000)(17,355,000)(17,280,000)(15,065,000)
Net loss:(29,583,000)(30,600,000)(22,928,000)(17,355,000)(17,280,000)(15,065,000)
Other undisclosed net income (loss) attributable to parent(186,000)1,575,0007,034,000 4,075,0003,189,000
Net loss available to common stockholders, diluted:(29,769,000)(29,025,000)(15,894,000)(17,355,000)(13,205,000)(11,876,000)

Comprehensive Income (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(29,583,000)(30,600,000)(22,928,000)(17,355,000)(17,280,000)(15,065,000)
Comprehensive loss:(29,583,000)(30,600,000)(22,928,000)(17,355,000)(17,280,000)(15,065,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(207,000)1,546,0007,010,00034,0004,071,0003,224,000
Comprehensive loss, net of tax, attributable to parent:(29,790,000)(29,054,000)(15,918,000)(17,321,000)(13,209,000)(11,841,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: